Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone
RATIONALE: Gathering information about how often methemoglobinemia occurs in young patients receiving dapsone for hematologic cancer or aplastic anemia may help doctors learn more about the disease and plan the best treatment.
PURPOSE: This research study is looking at methemoglobinemia in young patients with hematologic cancer or aplastic anemia treated with dapsone.
Chronic Myeloproliferative Disorders
Multiple Myeloma and Plasma Cell Neoplasm
Other: medical chart review
Procedure: assessment of therapy complications
|Official Title:||Dapsone Induced Methemoglobinemia in Pediatric Hematologic Malignancy and Aplastic Anemia|
- Incidence of methemoglobinemia in patients with hematologic malignancy or aplastic anemia who received dapsone prophylaxis through a retrospective chart review encompassing the last 15 years
- Major risk factors for developing methemoglobinemia
|Study Start Date:||January 2009|
|Primary Completion Date:||December 2009 (Final data collection date for primary outcome measure)|
- Define the incidence of methemoglobinemia in patients with hematologic malignancy or aplastic anemia who received dapsone prophylaxis through a retrospective chart review encompassing the last 15 years.
- Identify major risk factors for developing methemoglobinemia.
OUTLINE: Medical charts are reviewed. Of particular interest is demographic information, reasons for beginning dapsone prophylaxis, duration of dapsone prophylaxis, dapsone dosing, methemoglobin level, and treatment with methylene blue.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00993694
|United States, Tennessee|
|Vanderbilt-Ingram Cancer Center - Cool Springs|
|Nashville, Tennessee, United States, 37064|
|Vanderbilt-Ingram Cancer Center|
|Nashville, Tennessee, United States, 37232-6838|
|Principal Investigator:||Adam J. Esbenshade, MD||Vanderbilt-Ingram Cancer Center|